Life Sciences Archives - Page 12 of 22 - Becker's Hospital Review

FDA calls out Bristol Myers | How 4 GLP-1 makers fared in Q2 | Medicare drug price negotiations: 10 notes | The GLP-1 questions facing health systems

August 14, 2024 BHR Newsletter 1. How GLP-1 makers fared in Q2 Full story 2. Medicare drug price negotiations: 10 things to know Full story 3. The GLP-1 questions facing health systems Full story 4. Learn how Northwestern Medicine and…

FDA OKs 1st gene therapy for synovial sarcoma | VP picks' stance on pharmaceutical costs | 42% of online semaglutide sellers are illegal | Drug combo could boost cancer treatment efficacy

August 7, 2024 BHR Newsletter 1. FDA approves 1st gene therapy for synovial sarcoma Full story 2. Where VP picks stand on pharmaceutical costs Full story 3. 42% of online pharmacies selling semaglutide are illegal: Study Full story 4. Labor…

Obesity pill trial earns drugmaker $16B | US drugmaker on verge of closure | 4 notes on fall COVID vaccines | Could Amazon be headed for big healthcare losses?

July 31, 2024 BHR Newsletter 1. Another US drugmaker on the verge of closure: Report Full story 2. 25-person obesity pill trial earns drugmaker $16.8B Full story 3. Could Amazon be headed for big healthcare losses? Full story 4. 1…

The state of drug shortages | The 'best' weight loss drug remains elusive | Endo recalls mislabeled drug lot | 10 top execs that have left Optum

July 24, 2024 BHR Newsletter 1. 'Best' weight loss drug remains elusive Full story 2. 10 top execs that have recently left Optum Full story 3. The state of drug shortages: ASHP Full story 4. 1 MD is 'democratizing expertise'…

Faux-zempic' market on the rise | Rite Aid hit with security breach | Cancer drug shortage: 8 updates | JD Vance's healthcare record: 7 things to know

July 17, 2024 BHR Newsletter 1. A rising market for 'faux-zempic' Full story 2. JD Vance's healthcare record: What hospital leaders should know Full story 3. Cancer drug shortage: 8 updates Full story 4. Streamline your clinical trial workflow and…

Ozempic v. Mounjaro: Which came out on top | Eli Lilly plans $3B acquisition | PBMs dominate drug pricing: FTC | Insurers grab $50B from 'questionable' MA coding

July 10, 2024 BHR Newsletter 1. Eli Lilly plans for $3.2B purchase Full story 2. Insurers brought in $50B through 'questionable' Medicare Advantage coding: WSJ Full story 3. Ozempic vs. Mounjaro: Which fared better in 1st large study Full story…

Chevron ruling could stall news drugs | Biden tells Ozempic maker to 'Stop ripping off' Americans | FTC probes Teva | Moderna snags $176M for flu shot development

July 3, 2024 BHR Newsletter 1. Biden, Sanders to Ozempic maker: 'Stop ripping off' Americans Full story 2. Chevron ruling may hinder drug development, experts say Full story 3. FTC probes Teva over drug patents Full story 4. Health systems…

Eli Lilly sues phony drugmakers | Teva launches 1st generic GLP-1 | J&J buys biologics company for $850M | 5 drugs now in shortage

June 26, 2024 BHR Newsletter 1. J&J acquires immune disease biologics company for $850M Full story 2. Teva launches first generic GLP-1 Full story 3. Eli Lilly hits phony drugmakers with 6 more lawsuits Full story 4. Added ASC-covered procedures…

Novo Nordisk under Senate scrutiny | Bristol Myers Squibb to lay off 860+ | FDA panel passes potential Alzheimer's drug | Bill takes aim at healthcare 'corporate greed'

June 12, 2024 BHR Newsletter 1. Sanders calls vote to subpoena Novo Nordisk president Full story 2. Proposed legislation hopes to remove healthcare 'corporate greed': 7 things to know Full story 3. FDA panel votes in favor of Alzheimer's drug…

Novartis sues Maryland over 340B law | Sagent recalls 2 lots of cancer drug | Novo Nordisk races to boost Ozempic, Wegovy production | Fortune 500's top 25 healthcare cos.

June 5, 2024 BHR Newsletter 1. Novartis sues Maryland over law prohibiting restrictions on 340B drugs Full story 2. Fortune 500's top 25 healthcare companies Full story 3. Sagent recalls 2 lots of cancer drug Full story 4. It's time…